| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net proceeds from issuance of preferred stock and warrants | 15,019,700 | - |
| Net proceeds from issuance of common stock | 2,635,330 | 2,635,330 |
| Net cash provided by financing activities | 16,949,901 | 4,535,365 |
| Net decrease in cash and cash equivalents | 10,538,926 | 1,108,905 |
| Cash and cash equivalents at beginning of period | 864,840 | - |
| Cash and cash equivalents at end of period | 11,403,766 | - |
ORAGENICS INC (OGEN)
ORAGENICS INC (OGEN)